Monopar Therapeutics (NASDAQ:MNPR) PT Raised to $6.00

Monopar Therapeutics (NASDAQ:MNPR) had its price target upped by equities research analysts at HC Wainwright from $2.00 to $6.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 158.62% from the company’s previous close. HC Wainwright also issued estimates for Monopar Therapeutics’ Q1 2025 earnings at ($2.75) EPS, Q2 2025 earnings at ($2.80) EPS, Q3 2025 earnings at ($2.85) EPS, Q4 2025 earnings at ($1.50) EPS and FY2028 earnings at $0.90 EPS.

Monopar Therapeutics Stock Performance

MNPR stock traded down $0.10 during midday trading on Wednesday, hitting $2.32. 31,765 shares of the stock were exchanged, compared to its average volume of 450,548. The stock’s 50-day moving average price is $3.55 and its 200-day moving average price is $3.41. The stock has a market cap of $40.56 million, a price-to-earnings ratio of -4.46 and a beta of 1.18. Monopar Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $8.65.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Research analysts anticipate that Monopar Therapeutics will post -0.37 EPS for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.